Richard Francis
Found 4 recent publications
Teva Shares Hit 10-Year High Following FDA Approval for Schizophrenia Drug
Teva Pharmaceutical shares reached a ten-decade high following FDA approval for WELTRUZA. The milestone underscores the company's successful turnaround under CEO Richard Francis.
Teva’s Decade-Long Transformation: From Near-Collapse to Biopharma Growth
A decade after a severe financial crisis, Teva Pharmaceutical Industries is completing its turnaround under CEO Richard Francis, transitioning to common stock on the NYSE and advancing its innovative biopharma pipeline.
Investors are buying Teva's new story, and the company is aiming for the S&P 500 index
Teva's transformation from a generics manufacturer to an originator drug developer has pushed its market cap above $40 billion. The company is planning a direct listing in New York to facilitate its inclusion in the S&P 500 index.
Teva revenue beats expectations, profit misses: market reacts
Teva reported $4.1 billion in revenue, exceeding analyst forecasts. Net profit was 2 cents per share versus the expected 11 cents, due to Emalex acquisition costs. The company raised its annual revenue guidance, and shares are up over 4% in Tel Aviv.